Thermo Scientific Orbitrap GC-MS systems have been updated with new capabilities in high resolution accurate mass (HRAM) GC-MS, designed to provide users across metabolomics, food safety, environmental, pharma and toxicology applications with data accuracy.
           

Enhancements include the addition of Variable electron Voltage (VeV) technology, the Metabolomics Library and the TraceFinder Automated Compound Identification. These new capabilities aim to provide highly sensitive, selective and accurate compound identification of complex samples for both research and routine laboratories performing gas chromatography mass spectrometry (GC-MS). 
           
“The power of the multi-award winning Orbitrap GC-MS technology has facilitated numerous scientific advances and enabled our customers to break new ground and gain a deeper understanding of samples through the use of HRAM technology,” said Fausto Pigozzo, director of marketing, GC GC-MS, Thermo Fisher. “Our R&D teams are dedicated to advancing this technology and with these newest capabilities offer systems that continue to provide customers with information rich analysis.”
 
The new capabilities included on the Q Exactive GC Orbitrap and the Exactive GC Orbitrap, include:
·      VeV technology that enables low electron voltage settings to be used during electron ionization (EI) protocols, promoting high mass signals and providing high sensitivity for compounds prone to extensive fragmentation. 
·      The Orbitrap HRAM Metabolomics Library for electron ionization (EI), includes more than 800 metabolites and the spectra is refined and curated with the elemental composition of each EI fragment verified.
·      New TraceFinder software features a specialized spectral deconvolution library and automated compound identification to help enable identification of challenging compounds.
The Q Exactive GC Orbitrap is for compound discovery, identification and quantitation for comprehensive analyses. It’s designed to deliver sensitive, routine grade performance in both targeted and non-targeted screening protocols.